QUOTE AND NEWS
Globe Newswire  Jan 29  Comment 
CALGARY, Alberta, Jan. 29, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN). Skymark Research is currently
Globe Newswire  Jan 28  Comment 
NEW HAVEN, Conn., Jan. 28, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of a lead clinical candidate in its third proprietary program against hepatitis C infection. The candidate, ACH-2684,
Globe Newswire  Jan 25  Comment 
NEW HAVEN, Conn., Jan. 25, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D.
StreetInsider.com  Jan 22  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Achillion+Pharma+%28ACHN%29+Prices+10.28M+Shares+at+%242.08Share/5266923.html for the full story.
Globe Newswire  Jan 22  Comment 
NEW HAVEN, Conn., Jan. 22, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it has priced a firm
Globe Newswire  Jan 21  Comment 
NEW HAVEN, Conn., Jan. 21, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it intends to offer, subject
Globe Newswire  Jan 12  Comment 
DALLAS, Jan. 12, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company Achillion Pharmaceuticals Inc. (Nasdaq:ACHN). The report includes financial and investment analysis, analyst consensus, and
MarketWatch  Jan 11  Comment 
Drug stocks rose in early action Monday while shares of biotech group Achillion Pharmaceuticals rallied on positive Phase I data for its hepatitis C drug candidate ACH-1625. The NYSE Arca Pharmaceutical Index climbed 0.7% to 312.61 and the NYSE...
TheStreet.com  Jan 11  Comment 
Several stocks trading under $5 were poised to move on above-average volume during Monday's session.
Globe Newswire  Jan 11  Comment 
NEW HAVEN, Conn., Jan. 11, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported additional preliminary data from its on-going phase 1b clinical trial of ACH-1625 which demonstrated that the second dosing cohort



Thank you for your suggestion


You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):
 
ACHN AT A GLANCE
 
 
 
 
 
 
 
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki